



Speech Therapy – Single Service

Clinical Guidelines for Medical Necessity Review

Version: 1.0
Effective Date: December 29, 2023

Important Notices

Notices & Disclaimers:

GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2023 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2022 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Speech Language Pathology
Guideline Name: Speech Therapy (Single Service)

Literature review current through: 12/29/2023
Document last updated: 12/29/2023
Type: Adult (18+ yo) | Pediatric (0-17yo)

Table of Contents

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	4
Service: Speech Therapy	4
General Guidelines	4
Medical Necessity Criteria	5
Indications	5
Non-Indications	13
Level of Care Criteria	13
Procedure Codes (HCPCS/CPT)	14
Medical Evidence	16
References	17
Clinical Guideline Revision History/Information	22

Medical Necessity Criteria

Service: Speech Therapy

General Guidelines

- **Units, Frequency, & Duration:** The amount, frequency, and duration of the services must be reasonable under accepted standards of practice.¹ Cohere authorizes visits depending on the patient's progress. Please refer to the applicable payer policy for more specifics.
- **Criteria for Subsequent Requests:** Therapy is considered rehabilitative or maintenance. Rehabilitative therapy includes evaluations and re-evaluations; establishing treatment goals; developing a plan of care (e.g., procedures, frequency, and intensity of treatment); continued assessment at regular intervals; provision of patient instructions; selection of devices; and training patient and caregiver(s) to supplement treatment. Maintenance programs help the patient maintain functional status or to prevent or slow further deterioration in function. Skilled services may include the establishment of the maintenance program; delivery of the program; and determination of skilled care needs.² Please refer to the applicable payer policy for more specifics.
- **Recommended Clinical Approach:** Treatment should be ordered by a physician or licensed healthcare practitioner. Treatment requires the judgment, knowledge, and skills of a licensed and certified speech therapist and cannot be reasonably learned and implemented by non-professional or lay caregivers. Treatment meets Generally Accepted Standards of Practice and is targeted and effective in treating the individual's diagnosed impairment or condition. Treatment is expected to produce clinically significant and measurable improvement in the member's level of functioning within a reasonable and medically predictable period of time; alternatively, the treatment is part of a Medically Necessary program to prevent significant functional regression.
- **Exclusions:** None.

Medical Necessity Criteria

Indications

→ **Speech Therapy** is considered appropriate if **ANY** of the following is **TRUE**:

◆ **For aphasia** when **ALL** of the following are **TRUE**:

- Difficulty with **ANY** of the following³⁻⁴:
 - Verbal language comprehension⁵; **OR**
 - Written language comprehension⁵; **OR**
 - Expression of wants, needs, thoughts, or ideas; **OR**
 - Following directions; **OR**
 - Word finding; **OR**
 - Retrieval of single words⁶; **AND**
- A diagnosis as evidenced by **ANY** of the following:
 - Brain infection; **OR**
 - Brain tumor; **OR**
 - Neurodegenerative disorder (e.g., primary progressive aphasia)^{3-4,7}; **OR**
 - Stroke^{5,8}; **OR**
 - Traumatic brain injury; **AND**
- Symptoms when **ANY** of the following is **TRUE**:
 - Changes following a period of chronic or stable aphasia³⁻⁴; **OR**
 - Recent diagnosis of aphasia (e.g., secondary to stroke)⁵; **OR**

◆ **For acquired apraxia** when **ALL** of the following are **TRUE**:

- **ANY** of the following⁹⁻¹⁰:
 - The patient is aware of errors; **OR**
 - Decreased speech intelligibility; **OR**
 - Difficulty beginning speech or speech sounds; **OR**
 - Difficulty with spontaneous speech (can produce automatic speech); **OR**
 - Speech patterns are effortful but uncoordinated, with groping for sounds; **OR**
 - Impaired speech intonation; **OR**
 - Speech is slow and effortful; **OR**
 - Speech includes **ANY** of the following¹¹⁻¹²:
 - ◆ Additions; **OR**
 - ◆ Distortions; **OR**
 - ◆ Final consonant deletion; **OR**
 - ◆ Fronting; **OR**
 - ◆ Inconsistent substitutions; **OR**

- ◆ Omissions; **OR**
- ◆ Stopping; **OR**
- ◆ Substitutions; **OR**
- ◆ Use of wrong or nonsensical words; **AND**
- Vowel production is prolonged when articulating whole words; **AND**
- Symptoms when **ANY** of the following is **TRUE**¹³:
 - Changes following a period of chronic or stable apraxia of speech; **OR**
 - Recent diagnosis of apraxia of speech; **OR**
- ◆ **For cognitive-communication disorders** when **ALL** of the following are **TRUE**¹⁴:
 - The patient has difficulty with **ANY** of the following:
 - Attention, focus, or concentration; **OR**
 - Executive functioning (e.g., reasoning, problem-solving); **OR**
 - Expression of wants, needs, thoughts, or ideas; **OR**
 - Instrumental Activities of Daily Living (IADL); **OR**
 - Impulsive communication; **OR**
 - Interpersonal communication skills; **OR**
 - Memory¹⁵; **OR**
 - Pragmatic language skills (e.g., eye contact, affect, body language); **OR**
 - Verbal language comprehension; **OR**
 - Written language comprehension; **AND**
 - Symptoms when **ANY** of the following is **TRUE**:
 - Changes following a period of chronic or stable cognitive impairment; **OR**
 - Recent diagnosis of cognitive impairment; **OR**
- ◆ **For developmental language disorders** when **ALL** of the following are **TRUE**¹⁶:
 - **ANY** of the following:
 - Autism spectrum disorder or pervasive developmental disorder¹⁷⁻¹⁸; **OR**
 - Central nervous system infection (e.g., herpes encephalitis)¹⁹; **OR**
 - Cerebral palsy²⁰; **OR**
 - Child abuse; **OR**
 - Child neglect; **OR**
 - Developmental language disorder²¹; **OR**
 - Dyslexia; **OR**
 - Epilepsy; **OR**
 - Fetal alcohol spectrum disorder²²; **OR**
 - Hearing disorder²³; **OR**

- Inborn error of metabolism (e.g., phenylketonuria, galactosemia)¹⁹; **OR**
- Intellectual or developmental disability; **OR**
- Language disorder that is associated with a genetic syndrome²⁴⁻²⁵; **OR**
- Learning disabilities that are language-based²⁶; **OR**
- Low birth weight²⁷⁻²⁸; **OR**
- Premature birth²⁷; **OR**
- Receptive-expressive language impairment (e.g., mixed receptive-expressive language impairment)²⁹; **OR**
- Seizure disorder¹⁹; **AND**
- Impairment of function as evidenced by **ANY** of the following²⁶:
 - Decreased ability to recall specific information read or heard; **OR**
 - Decreased complexity and length of sentences or utterances; **OR**
 - Reduced expressive and receptive vocabulary; **OR**
 - Reduced literacy skills; **OR**
 - Challenges in organizing, planning, and articulating the content of spoken and written expressive language; **OR**
 - Impairments in pragmatic skills¹⁹; **OR**
 - Reduced Preliteracy skills; **OR**
 - Reduced social communication abilities³⁰; **OR**
 - Challenges with syntax and grammar in verbal and written language¹⁹; **OR**
 - Reduced verbal language comprehension/processing/expression; **OR**
 - Reduced written language comprehension/processing/expression; **AND**
- Symptoms when **ANY** of the following is **TRUE**:
 - Changes following a period of chronic or stable developmental language disorder; **OR**
 - Recent diagnosis of a language delay; **OR**
 - Recent diagnosis of a language disorder; **OR**
- ◆ **For developmental speech disorders** when **ALL** of the following are **TRUE**:
 - **ANY** of the following³¹:
 - Autism spectrum disorder or other pervasive developmental disorder¹⁷; **OR**
 - Cerebral palsy²⁰; **OR**
 - Childhood apraxia of speech³²; **OR**
 - Craniofacial disorders (e.g., cleft lip, cleft palate); **OR**

- Dental malocclusion with functional symptoms (e.g., difficulty biting, chewing); **OR**
- Epilepsy³³; **OR**
- Fetal alcohol spectrum disorder²²; **OR**
- Hearing disorder²³; **OR**
- Language disorder that is associated with a genetic syndrome; **OR**
- Low birth weight²⁷; **OR**
- Macroglossia; **OR**
- Microglossia; **OR**
- Premature birth²⁷; **OR**
- Primary developmental speech delay (e.g., articulation, phonologic delay); **OR**
- Velopharyngeal incompetence (e.g., nasal quality to speech); **AND**
- Impairment of function as evidenced by **ANY** of the following:
 - Articulators (lips, teeth, tongue, soft and hard palate) are not placed correctly; **OR**
 - Difficulty imitating speech; **OR**
 - Difficulty imitating speech sounds; **OR**
 - Hypernasality of speech; **OR**
 - Hyponasality of speech; **OR**
 - Hypotonic oral musculature; **OR**
 - Hypertonic oral musculature; **OR**
 - Sound repertoire is limited (e.g., consonants, vowels); **OR**
 - Patterns of immature speech errors (including simplification patterns) continue beyond norms according to the child's developmental age; **OR**
 - Challenges in oral-sensory perception; **OR**
 - Sound errors (not related to immaturity); **OR**
 - Speech intelligibility that is decreased; **OR**
 - Speech production is not equivalent to the ability to understand language; **OR**
 - Uncoordinated patterns of lips, tongue, and jaw; **OR**
 - Uncoordinated movements of lips, tongue, or jaw; **AND**
- Symptoms when **ANY** of the following is **TRUE**:
 - Changes following a period of chronic or stable developmental speech disorder; **OR**
 - Before surgery (eg., for cleft palate); **OR**
 - Recent diagnosis of a speech delay; **OR**
 - Recent diagnosis of a speech disorder; **OR**

◆ **For dysarthria** when **ALL** of the following are **TRUE**:

- **ANY** of the following³⁴:
 - Simulability for improved speech production; **OR**
 - Presence of **ANY** of the following:
 - ◆ Hypernasal resonance; **OR**
 - ◆ Audible nasal emission; **OR**
 - ◆ Loudness (as possibly diminished by damping effects of the nasal cavity); **OR**
 - ◆ “Strength” and precision of pressure consonants (e.g., function of velo pharygeal closure); **OR**
 - Connected speech with ratings across audiences (e.g., untrained versus familiar listeners); **OR**
 - Phonation; **OR**
 - Performance on articulation tests indicate differences in the accurate production of nasals and pressure consonants; **OR**
 - Difference in **ANY** of the following:
 - ◆ Intelligibility; **OR**
 - ◆ Pressure consonants; **OR**
 - ◆ Speaking effort; **OR**
 - ◆ Syllables per breath group; ; **OR**
 - ◆ Resonance with nares occluded versus unoccluded; **AND**
- Symptoms when **ANY** of the following is **TRUE**:
 - Changes following a period of chronic or stable dysarthria; **OR**
 - Recent diagnosis of dysarthria; **OR**
 - The patient had **ANY** of the following for head and neck cancer:
 - ◆ Surgery; **OR**
 - ◆ Radiation therapy; **OR**
 - ◆ Chemotherapy; **OR**
- ◆ **For dysphagia** when **ALL** of the following are **TRUE**:
 - Initial therapy with **ALL** of the following:
 - Dysphagia as evidenced by **ANY** of the following:
 - ◆ Craniofacial disorder, including cleft lip or palate³⁵; **OR**
 - ◆ Swallowing difficulty associated with **ANY** of the following:
 - Neurologic disease (e.g., stroke, Parkinson disease)³⁶; **OR**
 - Weight loss or evidence of malnutrition³⁷; **OR**
 - Xerostomia³⁸; **OR**
 - ◆ **ANY** of the following³⁹:

- Aspiration of liquids or food^{37,38,40}; **OR**
- Aspiration pneumonia; **OR**
- Recurrent pneumonias; **OR**
- Difficulty initiating swallow; **OR**
- Difficulty managing and controlling food, liquid, or saliva in oral cavity; **OR**
- Drooling or excessive secretions; **OR**
- Eating time is prolonged³⁸; **OR**
- Food becomes stuck in the patient's throat; **OR**
- Penetration of liquids or food^{38,40}; **OR**
- **ANY** of the following³⁸:
 - Congestion; **OR**
 - Coughing; **OR**
 - Throat clearing; **OR**
 - Nasal regurgitation; **OR**
 - Wet-sounding voice; **OR**
 - Choking; **OR**
- Oral cavity has a decreased sensation; **OR**
- Swallow reflex is delayed; **OR**
- Infant with **ANY** of the following:
 - Abnormal suckling, sucking, rooting, or phasic bite reflex; **OR**
 - Decreased jaw, head, or trunk control; **OR**
 - Diminished suck, swallow, and breath patterns or rhythm; **OR**
 - Gag, choke, cough, or biting during intake; **OR**
 - History of extended nonoral feeding methods or tracheostomy; **OR**
 - Impaired tone, posture, and quality of movement of oral musculature; **OR**
- Multiple swallows to clear oral cavity; **OR**
- Nasal regurgitation; **OR**
- Pocketing food in buccal cavity³⁸; **OR**
- Signs of silent aspiration including **ANY** of the following:
 - Weak or absent cough; **OR**
 - Change in body temperature after eating; **OR**
 - Wet or hoarse voice when eating or drinking⁴⁰; **AND**

- Symptoms when **ANY** of the following is **TRUE**:
 - ◆ Change following a period of chronic or stable dysphagia; **OR**
 - ◆ Recent diagnosis of dysphagia; **OR**
 - ◆ Recent head and neck surgery (e.g., thyroidectomy, head and neck cancer)⁴¹; **OR**
 - ◆ Recent insertion of implant or prosthesis, radiation therapy, or chemotherapy for head and neck cancer⁴¹; **OR**
- ◆ **For voice disorders** when **ANY** of the following is **TRUE**:
 - The patient requires an assessment before **ANY** of the following that relate to head or neck cancer:
 - Surgery; **OR**
 - Radiation therapy; **OR**
 - Chemotherapy; **OR**
 - For initial therapy when **ALL** of the following are **TRUE**:
 - A voice disorder with **ANY** of the following:
 - ◆ **ANY** of the following speech abnormalities:
 - Loudness; **OR**
 - Pitch; **OR**
 - Quality; **OR**
 - ◆ Alaryngeal speech⁴²; **OR**
 - ◆ Aphonia⁴³; **OR**
 - ◆ Dysphonia⁴³; **OR**
 - ◆ Chronic laryngitis; **OR**
 - ◆ Functional dysphonia; **OR**
 - ◆ Hoarseness (dysphonia)⁴³; **OR**
 - ◆ Hypernasality; **OR**
 - ◆ Hyponasality; **OR**
 - ◆ Laryngeal trauma; **OR**
 - ◆ Mechanical ventilator-dependent patient; **OR**
 - ◆ Mutational falsetto; **OR**
 - ◆ Paradoxical vocal cord movement; **OR**
 - ◆ Spasmodic dysphonia⁴⁴; **OR**
 - ◆ **ANY** of the following vocal cord abnormalities:
 - Nodules; **OR**
 - Ulcers; **OR**
 - Polyps; **OR**
 - Thickening; **OR**
 - Granulomas; **OR**
 - ◆ Vocal cord paresis; **OR**
 - ◆ Vocal cord paralysis; **OR**
 - ◆ Voice-gender incongruence (when services are related to gender-affirming care)⁴⁵; **OR**
 - ◆ Voice tremor; **OR**

- ◆ Xerostomia; **AND**
- Symptoms when **ANY** of the following is **TRUE**:
 - ◆ Changes following a period of chronic or stable voice disorder; **OR**
 - ◆ Recent diagnosis of voice disorder; **OR**
 - ◆ Symptoms that reoccur after **ANY** of the following for head and neck cancer:
 - Surgery; **OR**
 - Insertion of implant or prosthesis; **OR**
 - Radiation therapy; **OR**
 - Chemotherapy⁴²; **OR**
- ◆ **For re-evaluation** when **ALL** of the following are **TRUE**:
 - There was a break from therapy as requested by the patient or provider; **AND**
 - Documentation of progress from previous speech therapy; **AND**
 - Progress is expected if therapy resumes; **OR**
- ◆ **For extended therapy** as evidenced by **ALL** of the following⁴⁶:
 - **ANY** of the following:
 - Functional progress was achieved during initial therapy, but additional therapy is needed; **OR**
 - Maintenance therapy is needed for **ANY** of the following:
 - ◆ To prevent additional deterioration; **OR**
 - ◆ To preserve existing function; **AND**
 - Targeted skills are crossing into the natural environment; **AND**
 - The patient is actively participating in therapy; **AND**
 - Therapy goals not yet achieved; **AND**
 - If applicable, before surgery, radiation therapy, or chemotherapy for head and neck cancer; **AND**
 - If applicable, the patient has an active home regimen; **OR**
- ◆ **For electronic augmentative communication devices** when **ALL** of the following are **TRUE**⁴⁷:
 - Inability to communicate effectively due to a speech disorder⁴⁸; **AND**
 - Functional ability to use the covered device (e.g., hearing, literacy, motor function, visual function, cognitive function)⁴⁹; **AND**
 - Patient and caregiver(s) support the use of the device⁵⁰; **AND**
 - “Yes/no” responses can be demonstrated by the patient; **AND**
 - Communication is possible using pictures and/or words; **AND**

- Electronic Augmentative Communication Device is recommended by SLP since gestures, writing, and non-electronic options are deemed inadequate for daily communication needs.⁵¹

Non-Indications

→ **Speech Therapy** is not considered appropriate if **ANY** of the following is **TRUE**¹:

- ◆ Non-diagnostic, non-therapeutic, routine, repetitive, and reinforcing procedures (e.g., practicing word drills without skilled feedback); **OR**
- ◆ Procedures which are repetitive and/or that reinforce previously learned material; **OR**
- ◆ Procedures which may be effectively carried out with the individual by a non-professional (e.g., family, restorative aide) after instruction is completed; **OR**
- ◆ Services rendered by a SLP assistant or aide; **OR**
- ◆ Provision of practice for use of augmentative or alternative communication systems after being taught their use; **OR**
- ◆ Laryngoscopy for medical diagnostic purposes performed by a non-physician; **OR**
- ◆ Group therapy sessions; **OR**
- ◆ Services for chronic disorders of memory and orientation without significant functional progress; **OR**
- ◆ Supervision of the use of memory aids (e.g., memory books, memory boards, or communication books); **OR**
- ◆ Services provided by a non-licensed SLP (e.g., SLP assistant or aide); **OR**
- ◆ Services and treatment for **ANY** of the following disorders:
 - Fluency disorder; **OR**
 - Conceptual handicap; **OR**
 - Dysprosody; **OR**
 - Stuttering and cluttering (except neurogenic stuttering caused by acquired brain damage); **OR**
 - Myofunctional disorders, e.g., tongue thrust; **OR**
- ◆ When services are provided by a public agency (e.g., school district).

Level of Care Criteria

Outpatient.

Procedure Codes (HCPCS/CPT)

HCPCS/CPT Code	Code Description
92609	Therapeutic services for the use of speech-generating device, including programming and modification
92520	Laryngeal function studies (i.e., aerodynamic testing and acoustic testing)
92606	Therapeutic service(s) for the use of non-speech-generating device, including programming and modification
92610	Evaluation of oral and pharyngeal swallowing function
92630	Auditory rehabilitation; prelingual hearing loss
92633	Auditory rehabilitation; postlingual hearing loss
97129	Therapeutic interventions that focus on cognitive function (e.g., attention, memory, reasoning, executive function, problem-solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (e.g., managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15 minutes
97130	Therapeutic interventions that focus on cognitive function (e.g., attention, memory, reasoning, executive function, problem-solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (e.g., managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)
S9152	Speech therapy, re-evaluation

V5362	Speech screening
V5363	Language screening
V5364	Dysphagia screening

Medical Evidence

The following have been published by national and specialty organizations on the topic of speech therapy.

The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) published a clinical practice guideline on *Hoarseness (Dysphonia)*. The aim of the guideline is to improve patient quality of care outcomes. Objectives include reducing inappropriate variations in care, producing optimal health outcomes, and minimizing patient harm. Highlights of the updated guideline include evidence profiles to emphasize patient preferences, confidence in the evidence, differences of opinion, and quality improvement opportunities.⁴³

The American Speech Language Hearing Association (ASHA) published *Speech–Language Pathology Medical Review Guidelines*. An overview is provided of SLP qualifications, standard practices, descriptions of services, documentation of services, and treatment efficacy data. The ASHA guideline also includes guidance on assessment, diagnosis, treatment, and referral of individuals requiring SLP services.²

The United States Preventive Services Task Force (USPSTF) is currently updating a recommendation statement from 2015 on *Screening for Speech and Language Delay and Disorders in Children Age 5 Years or Younger*. Evidence is insufficient to assess the balance of benefits and harms of screening for speech and language delay and disorders for this population.⁵²

References

1. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Speech-language pathology (L34046). Revision Effective Date August 3, 2023. Accessed December 20, 2023. <https://www.cms.gov/medicare-coverage-database/search.aspx>.
2. American Speech Language Hearing Association (ASHA). Speech-language pathology medical review guidelines. Published 2015. Accessed December 18, 2023. <https://www.asha.org/siteassets/uploadedfiles/slp-medical-review-guidelines.pdf>.
3. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011 Mar 15;76(11):1006-14. doi: 10.1212/WNL.0b013e31821103e6. PMID: 21325651; PMCID: PMC3059138.
4. Grossman M. Primary progressive aphasia: Clinicopathological correlations. *Nat Rev Neurol*. 2010 Feb;6(2):88-97. doi: 10.1038/nrneurol.2009.216. PMID: 20139998; PMCID: PMC3637977.
5. González-Fernández m, Christian AB, Davis C, et al. Role of aphasia in discharge location after stroke. *Arch Phys Med Rehabil*. 2013 May;94(5):851-5. doi: 10.1016/j.apmr.2012.11.042. PMID: 23237764; PMCID: PMC3678960.
6. Jacquemot C, Dupoux E, Robotham L, et al. Specificity in rehabilitation of word production: A meta-analysis and a case study. *Behav Neurol*. 2012;25(2):73-101. doi: 10.3233/BEN-2012-0358. PMID: 22425722; PMCID: PMC5294258.
7. Kelley RE, El-Khoury R. Frontotemporal dementia. *Neurol Clin*. 2016 Feb;34(1):171-81. doi: 10.1016/j.ncl.2015.08.007. PMID: 26613998; PMCID: PMC5549462.
8. Brady MC, Kelly H, Godwin J, et al. Speech and language therapy for aphasia following stroke. *Cochrane Database Syst Rev*. 2016 Jun 1;2016(6):CD000425. doi: 10.1002/14651858.CD000425.pub4. PMID: 27245310; PMCID: PMC8078645.
9. Hurkmans J, Jonkers R, Boonstra AM, et al. Assessing the treatment effects in apraxia of speech: Introduction and evaluation of the Modified Diadochokinesis Test. *Int J Lang Commun Disord*. 2012 Jul-Aug;47(4):427-36. doi: 10.1111/j.1460-6984.2012.00155.x. PMID: 22788228.
10. West C, Hesketh A, Vail A, et al. Interventions for apraxia of speech following stroke. *Cochrane Database Syst Rev*. 2005 Oct 19;2005(4):CD004298. doi: 10.1002/14651858.CD004298.pub2. PMID: 16235357; PMCID: PMC8769681.
11. Bislick L, McNeil M, Spencer KA, et al. The nature of error consistency in individuals with acquired apraxia of speech and aphasia. *Am J Speech*

- Lang Pathol.* 2017 Jun 22;26(2S):611-630. doi: 10.1044/2017_AJSLP-16-0080. PMID: 28654943; PMCID: PMC5576968.
12. American Speech-Language-Hearing Association (ASHA). Speech sound disorders - articulation and phonology. Updated 2022. Accessed December 17, 2023. <https://www.asha.org/Practice-Portal/Clinical-Topics/Articulation-and-Phonology/>.
 13. Wambaugh JL. Treatment guidelines for acquired apraxia of speech: treatment descriptions and recommendations. *J Med Speech-Lang PA.* 2006;14(2):xxxv - lxvii. https://www.ancds.org/assets/docs/EBP/wambaugh_06b.pdf.
 14. Turkstra LS, Politis AM, Forsyth R. Cognitive-communication disorders in children with traumatic brain injury. *Dev Med Child Neurol.* 2015 Mar;57(3):217-22. doi: 10.1111/dmcn.12600. PMID: 25283953.
 15. Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. *Cochrane Database Syst Rev.* 2014 Feb 11;(2):CD009131. doi: 10.1002/14651858.CD009131.pub3. PMID: 24515630.
 16. Law J, Garrett Z, Nye C. Speech and language therapy interventions for children with primary speech and language delay or disorder. *Cochrane Database Syst Rev.* 2003;2003(3):CD004110. doi: 10.1002/14651858.CD004110. PMID: 12918003; PMCID: PMC8407295.
 17. Hyman SL, Levy SE, Myers SM, et al. Identification, evaluation, and management of children with autism spectrum disorder. *Pediatrics.* 2020 Jan;145(1):e20193447. doi: 10.1542/peds.2019-3447. PMID: 31843864.
 18. Friedman L, Sterling A. A review of language, executive function, and intervention in autism spectrum disorder. *Semin Speech Lang.* 2019 Aug;40(4):291-304. doi: 10.1055/s-0039-1692964. PMID: 31311054; PMCID: PMC7012379.
 19. Dennis M. Language disorders in children with central nervous system injury. *J Clin Exp Neuropsychol.* 2010 Apr;32(4):417-32. doi: 10.1080/13803390903164355. PMID: 20397297; PMCID: PMC3057107.
 20. Pennington L, Goldbart J, Marshall J. Speech and language therapy to improve the communication skills of children with cerebral palsy. *Cochrane Database Syst Rev.* 2004;2004(2):CD003466. doi: 10.1002/14651858.CD003466.pub2. PMID: 15106204; PMCID: PMC8407241.
 21. Bishop DVM, Snowling MJ, Thompson PA, et al. Phase 2 of CATALISE: A multinational and multidisciplinary Delphi consensus study of problems with language development: Terminology. *J Child Psychol Psychiatry.* 2017 Oct;58(10):1068-1080. doi: 10.1111/jcpp.12721. PMID: 28369935; PMCID: PMC5638113.
 22. Williams JF, Smith VC, Committee on Substance Abuse. Fetal alcohol spectrum disorders. *Pediatrics.* 2015 Nov;136(5):e1395-406. doi: 10.1542/peds.2015-3113. PMID: 26482673.
 23. Joint Committee on Infant Hearing of the American Academy of Pediatrics; Muse C, Harrison J, et al. Supplement to the JCIH 2007

- position statement: Principles and guidelines for early intervention after confirmation that a child is deaf or hard of hearing. *Pediatrics*. 2013 Apr;131(4):e1324-49. doi: 10.1542/peds.2013-0008. PMID: 23530178.
24. McDuffie A, Banasik A, Bullard L, et al. Distance delivery of a spoken language intervention for school-aged and adolescent boys with fragile X syndrome. *Dev Neurorehabil*. 2018 Jan;21(1):48-63. doi: 10.1080/17518423.2017.1369189. PMID: 28956679; PMCID: PMC5986725.
 25. Danielsson H, Henry L, Messer D, et al. Developmental delays in phonological recoding among children and adolescents with Down syndrome and Williams syndrome. *Res Dev Disabil*. 2016 Aug;55:64-76. doi: 10.1016/j.ridd.2016.03.012. PMID: 27043367.
 26. Hulme C, Snowling MJ. Reading disorders and dyslexia. *Curr Opin Pediatr*. 2016 Dec;28(6):731-735. doi: 10.1097/MOP.0000000000000411. PMID: 27496059; PMCID: PMC5293161.
 27. Northam GB, Liégeois F, Chong WK, et al. Speech and oromotor outcome in adolescents born preterm: Relationship to motor tract integrity. *J Pediatr*. 2012 Mar;160(3):402-408.e1. doi: 10.1016/j.jpeds.2011.08.055. PMID: 22000302; PMCID: PMC3657185.
 28. Ribeiro LA, Zachrisson HD, Schjolberg S, et al. Attention problems and language development in preterm low-birth-weight children: Cross-lagged relations from 18 to 36 months. *BMC Pediatr*. 2011 Jun 29;11:59. doi: 10.1186/1471-2431-11-59. PMID: 21714885; PMCID: PMC3163534.
 29. Boyle J, McCartney E, O'Hare A, et al. Intervention for mixed receptive-expressive language impairment: A review. *Dev Med Child Neurol*. 2010 Nov;52(11):994-9. doi: 10.1111/j.1469-8749.2010.03750.x. PMID: 20813021.
 30. Bakopoulou I, Dockrell JE. The role of social cognition and prosocial behaviour in relation to the socio-emotional functioning of primary aged children with specific language impairment. *Res Dev Disabil*. 2016 Feb-Mar;49-50:354-70. doi: 10.1016/j.ridd.2015.12.013. PMID: 26773217.
 31. McLaughlin MR. Speech and language delay in children. *Am Fam Physician*. 2011 May 15;83(10):1183-8. PMID: 21568252.
 32. Morgan AT, Murray E, Liégeois FJ. Interventions for childhood apraxia of speech. *Cochrane Database Syst Rev*. 2018 May 30;5(5):CD006278. doi: 10.1002/14651858.CD006278.pub3. PMID: 29845607; PMCID: PMC6494637.
 33. Rejnö-Habte Selassie G, Viggedal G, Olsson I, et al. Speech, language, and cognition in preschool children with epilepsy. *Dev Med Child Neurol*. 2008 Jun;50(6):432-8. doi: 10.1111/j.1469-8749.2008.02060.x. PMID: 18422681.
 34. Yorkston KM, Spencer K, Duffy J, et al. Evidence-based practice guidelines for dysarthria: Management of velopharyngeal function. *J Med Speech-Lang PA*. 2021. 9(4):257-74.
 35. Lewis CW, Jacob LS, Lehmann CU, et al. The primary care pediatrician and the care of children with cleft lip and/or cleft palate. *Pediatrics*. 2017 May;139(5):e20170628. doi: 10.1542/peds.2017-0628. PMID: 28557774.

36. Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: A randomized trial. *Neurology*. 2010 Nov 23;75(21):1912–9. doi: 10.1212/WNL.0b013e3181fef115. PMID: 21098406; PMCID: PMC2995389.
37. Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies - report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. *Neurology*. 2014 Oct 14;83(16):1453–63. doi: 10.1212/WNL.0000000000000892. PMID: 25313375; PMCID: PMC4206155.
38. Christmas C, Rogus-Pulia N. Swallowing disorders in the older population. *J Am Geriatr Soc*. 2019 Dec;67(12):2643–2649. doi: 10.1111/jgs.16137. PMID: 31430395; PMCID: PMC7102894.
39. Wirth R, Dziewas R, Beck AM, et al. Oropharyngeal dysphagia in older persons - from pathophysiology to adequate intervention: A review and summary of an international expert meeting. *Clin Interv Aging*. 2016 Feb 23;11:189–208. doi: 10.2147/CIA.S97481. PMID: 26966356; PMCID: PMC4770066.
40. Adil E, Al Shemari H, Kacprowicz A, et al. Evaluation and management of chronic aspiration in children with normal upper airway anatomy. *JAMA Otolaryngol Head Neck Surg*. 2015 Nov;141(11):1006–11. doi: 10.1001/jamaoto.2015.2266. PMID: 26501239.
41. Govender R, Smith CH, Taylor SA, et al. Swallowing interventions for the treatment of dysphagia after head and neck cancer: A systematic review of behavioural strategies used to promote patient adherence to swallowing exercises. *BMC Cancer*. 2017 Jan 10;17(1):43. doi: 10.1186/s12885-016-2990-x. PMID: 28068939; PMCID: PMC5223405.
42. Lewin JS, Baumgart LM, Barrow MP, et al. Device life of the tracheoesophageal voice prosthesis revisited. *JAMA Otolaryngol Head Neck Surg*. 2017 Jan 1;143(1):65–71. doi: 10.1001/jamaoto.2016.2771. PMID: 27684464; PMCID: PMC5322740.
43. Stachler RJ, Francis DO, Schwartz SR, et al. Clinical practice guideline: Hoarseness (dysphonia) (update). *Otolaryngol Head Neck Surg*. 2018 Mar;158(1_suppl):S1–S42. doi: 10.1177/0194599817751030. PMID: 29494321.
44. Simonyan K, Barkmeier-Kraemer J, Blitzer A, et al. Laryngeal dystonia: Multidisciplinary update on terminology, pathophysiology, and research priorities. *Neurology*. 2021 May 25;96(21):989–1001. doi: 10.1212/WNL.00000000000011922. PMID: 33858994; PMCID: PMC8205448.
45. Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. *Int J Transgend Health*. 2022 Sep 6;23(Suppl 1):S1–S259. doi: 10.1080/26895269.2022.2100644. PMID: 36238954; PMCID: PMC9553112.
46. Houtrow A, Murphy N, Council on Children with Disabilities. Prescribing physical, occupational, and speech therapy services for children with

- disabilities. *Pediatrics*. 2019 Apr;143(4):e20190285. doi: 10.1542/peds.2019-0285. PMID: 30910917.
47. Brady NC, Bruce S, Goldman A, et al. Communication services and supports for individuals with severe disabilities: Guidance for assessment and intervention. *Am J Intellect Dev Disabil*. 2016 Mar;121(2):121-38. doi: 10.1352/1944-7558-121.2.121. PMID: 26914467; PMCID: PMC4770561.
48. Ganz JB, Mason R, Goodwyn FD, et al. Interaction of participant characteristics and type of AAC with individuals with ASD: A meta-analysis. *Am J Intellect Dev Disabil*. 2014 Nov;119(6):516-35. doi: 10.1352/1944-7558-119.6.516. PMID: 25354122.
49. Fried-Oken M, Kinsella M, Peters B, et al. Human visual skills for brain-computer interface use: A tutorial. *Disabil Rehabil Assist Technol*. 2020 Oct;15(7):799-809. doi: 10.1080/17483107.2020.1754929. PMID: 32476516; PMCID: PMC7529781.
50. King M, Ronski M, Sevcik RA. Growing up with AAC in the digital age: a longitudinal profile of communication across contexts from toddler to teen. *Augment Altern Commun*. 2020 Jun;36(2):128-141. doi: 10.1080/07434618.2020.1782988. PMID: 32706274; PMCID: PMC8281386.
51. Lund SK, Quach W, Weissling K, et al. Assessment with children who need augmentative and alternative communication (AAC): Clinical decisions of AAC specialists. *Lang Speech Hear Serv Sch*. 2017 Jan 1;48(1):56-68. doi: 10.1044/2016_LSHSS-15-0086. PMID: 28114681.
52. United States Preventive Services Task Force (USPSTF). Speech and language delay and disorders in children: Screening. Updated July 25, 2023. Accessed December 18, 2023. <https://www.uspreventiveservicestaskforce.org/uspstf/draft-update-summary/speech-language-delay-disorders-children-age-5-years-younger-screening>.

Clinical Guideline Revision History/Information

Original Date: December 29, 2023	
Review History	